Lantheus Earnings: What To Look For From LNTH

Radiopharmaceutical company Lantheus Holdings (NASDAQ:LNTH) will be reporting earnings this Thursday before the bell. Here’s what to expect.

Lantheus beat analysts’ revenue expectations last quarter, reporting revenues of $384 million, up 1.4% year on year. It was a strong quarter for the company, with an impressive beat of analysts’ revenue estimates and full-year revenue guidance slightly topping analysts’ expectations.

This quarter, the market is expecting Lantheus’s revenue to decline 6.3% year on year, a reversal from the 10.5% increase it recorded in the same quarter last year.

Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Lantheus has missed Wall Street’s revenue estimates multiple times over the last two years.

Looking at Lantheus’s peers in the medical devices & supplies - imaging, diagnostics segment, some have already reported their Q4 results, giving us a hint as to what we can expect. GE HealthCare delivered year-on-year revenue growth of 7.1%, beating analysts’ expectations by 1.7%, and QuidelOrtho reported revenues up 2.2%, topping estimates by 3.2%. GE HealthCare traded up 4.5% following the results while QuidelOrtho was down 17.6%.

Debates around the economy’s health and the impact of potential tariffs and corporate tax cuts have caused much uncertainty in 2025. While some of the medical devices & supplies - imaging, diagnostics stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 3.7% on average over the last month. Lantheus is up 9.7% during the same time and is heading into earnings with an average analyst price target of $85 (compared to the current share price of $74.31).